Contact Us
Subscribe to this blog via RSS
Join us on LinkedInCategories
- Data Privacy
- Department of Health and Human Services' Office of Civil Rights
- Medical Malpractice
- Medical Cannabis
- Workplace health
- Workplace Violence
- Assisted Living Facilities
- EMTALA
- FDA
- Reproductive Rights
- Roe v. Wade
- SCOTUS
- COVID-19
- Prescription Drugs
- Telemedicine
- Medical Spas
- Code Enforcement
- Corporate
- United States Department of Justice ("DOJ")
- Employee Contracts
- Non-Compete Agreement
- Compliance
- HIPAA
- Kentucky Board of Nursing
- Managed Care Organizations (“MCOs”)
- Primary Care Physicians ("PCPs")
- Accountable Care Organizations (“ACO”)
- Anti-Kickback Statute
- Data Breach
- Electronic Protected Health Information (ePHI)
- False Claims Act
- Health Information Technology for Economic and Clinical Health Act (HITECH Act)
- Health Insurance Portability and Accountability Act of 1996 (HIPAA)
- HPSA
- KASPER
- Kentucky Board of Medical Licensure
- Kentucky’s Department for Medicaid Services
- Medicaid
- Mental Health Care
- Office for Civil Rights ("OCR")
- Office of Inspector General of the United States Department of Health and Human Services (OIG)
- Patient Protection and Affordable Care Act (“ACA”)
- Pharmacists
- Physician Assistants
- Qui Tam
- Stark Laws
- Affordable Care Act
- APRNs
- Centers for Medicare & Medicaid Services (“CMS”)
- Charitable Hospitals
- Federally Qualified Health Centers (“FQHCs”)
- Health Professional Shortage Area ("HPSA")
- Hospitals
- HRSA
- Medicare
- Mid-Level Practitioners
- Rural Health Centers (“RHCs”)
- Rural Health Clinic
- Telehealth
- Business Associate Agreements
- Compliance Programs
- ERISA
- Fraud
- Hospice
- Overpayments
- Part D
- Appeal
- Electronic Health Records (“EHR")
- Advanced Practice Registered Nurses
- Business Associates
- Denied Claims
- Division of Regulated Child Care
- Employee Agreement
- Fair Labor Standards Act (FLSA)
- Licensed practical nurses (LPN)
- Licensure Requirements
- Nurse practitioners (NP)
- Part A
- Part B
- Patient Autonomy
- Personal Health Information
- Personal Service Entities
- Physician Payments
- Qualified Health Plan ("QHP")
- Registered nurses (RN)
- Abuse and Waste
- Occupational Safety and Health Administration (“OSHA”)
- Department of Health and Human Services (HHS)
- Health Insurance
- Healthcare Regulation
- Health Care Law
McBrayer Blogs
Controlling Compounding: The Drug Quality and Security Act
In October 2012, a fatal meningitis outbreak killed 64 people in the United States and infected more than 750 in 20 states. The outbreak was traced back to contaminated vials of an injectable painkilling steroid that was compounded by the New England Compounding Center (“NECC”).
Compounding, as the process by which a pharmacist combines drug ingredients per a doctor’s prescription to meet the unique needs of an individual, is nothing new. In recent years, however, the practice has experienced a surge in popularity as more Americans have come to expect tailored medicine and drug shortages create a persistent need to compound unavailable drugs. Historically, compounding involved a relationship between the compounding pharmacist, physician, and patient – compounding was done at the local pharmacy. Now, compounding facilities mix and compound mass quantities of product for interstate sale.
As a result of the meningitis outbreak in 2012, many called for increased regulatory oversight of compounding centers like NECC. Historically, States are responsible for regulating retail pharmacies, while the FDA regulates drug manufacturers. Compounding centers are somewhat of an anomaly – not fitting into either the retail pharmacy or manufacturer category. The 2012 meningitis tragedy garnered the attention of Congress and, after several false starts, House Bill 3204 was introduced in September, 2013. The bill, known as the Drug Quality and Security Act (“DQSA”) passed on November 18, 2013, with President Obama signing the legislation into law last week on November 27th.
The DQSA establishes and regulates a new class of pharmacies known as “outsourcing facilities.” Outsourcing facilities are newly defined as those engaged in the compounding of sterile drugs that register with the FDA. An outsourcing facility may compound without obtaining individual patient prescriptions. To learn more about the DQSA, visit the blog again on Thursday.
Services may be performed by others.
This article does not constitute legal advice.
